PE20120224A1 - Derivados de 1h-imidazo-[4,5-c]-quinolinona - Google Patents

Derivados de 1h-imidazo-[4,5-c]-quinolinona

Info

Publication number
PE20120224A1
PE20120224A1 PE2011002047A PE2011002047A PE20120224A1 PE 20120224 A1 PE20120224 A1 PE 20120224A1 PE 2011002047 A PE2011002047 A PE 2011002047A PE 2011002047 A PE2011002047 A PE 2011002047A PE 20120224 A1 PE20120224 A1 PE 20120224A1
Authority
PE
Peru
Prior art keywords
imidazo
methyl
dimetoxy
ona
quinolin
Prior art date
Application number
PE2011002047A
Other languages
English (en)
Inventor
Pascal Furet
Frank Stepham Kalthoff
Robert Mah
Christian Ragot
Frederic Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120224A1 publication Critical patent/PE20120224A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1H-IMIDAZO-[4,5-c]-QUINOLINONA DE FORMULA (I) DONDE X ES O O S; Y ES CH O N; R1 ES HETEROARILO DE 5 MIEMBROS OPCIONALMENTE SUSTITUIDO CON ALQUILO, HALOGENO, AMINO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C4) O ALQUENILO(C2-C4); R3 ES ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXILO, ALCOXILO, ENTRE OTROS, O HETEROCICLILO; R4, R5 Y R6 SON CADA UNO H. SON COMPUESTOS PREFERIDOS: 8-(3,4-DIMETOXI-FENIL)-1-(1,5-DIMETIL-1H-PIRAZOL-4-IL)-3-METIL-1,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-2-ONA; 8-(3,4-DIMETOXI-FENIL)-1-(2-ETIL-2H-PIRAZOL-3-IL)-3-METIL-1,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-2-ONA; 8-(3,4-DIMETOXI-FENIL)-3-METIL-1-(2-METIL-2H-PIRAZOL-3-IL)-1,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-2-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) SIENDO UTILES EN EL TRATAMIENTO DE LEUCEMIA, MIELOFIBROSIS CON METAPLASIA MIELOIDE, QUERATOSIS ACTINICA, PSORIASIS
PE2011002047A 2009-06-04 2010-06-02 Derivados de 1h-imidazo-[4,5-c]-quinolinona PE20120224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
PE20120224A1 true PE20120224A1 (es) 2012-04-04

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002047A PE20120224A1 (es) 2009-06-04 2010-06-02 Derivados de 1h-imidazo-[4,5-c]-quinolinona

Country Status (30)

Country Link
US (2) US8476294B2 (es)
EP (1) EP2438064A1 (es)
JP (1) JP5596137B2 (es)
KR (1) KR101445458B1 (es)
CN (1) CN102574845B (es)
AR (1) AR076949A1 (es)
AU (1) AU2010255727B2 (es)
BR (1) BRPI1010621A2 (es)
CA (1) CA2763821A1 (es)
CL (1) CL2011003052A1 (es)
CO (1) CO6470887A2 (es)
CR (1) CR20110608A (es)
CU (1) CU24064B1 (es)
DO (1) DOP2011000373A (es)
EA (1) EA020715B1 (es)
EC (1) ECSP11011500A (es)
GE (1) GEP20156267B (es)
IL (1) IL216452A0 (es)
MA (1) MA33332B1 (es)
MX (1) MX2011012943A (es)
NI (1) NI201100209A (es)
NZ (1) NZ596487A (es)
PE (1) PE20120224A1 (es)
SG (1) SG176572A1 (es)
TN (1) TN2011000626A1 (es)
TW (1) TWI464168B (es)
UA (1) UA106074C2 (es)
UY (1) UY32682A (es)
WO (1) WO2010139731A1 (es)
ZA (1) ZA201108439B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
US20130310374A1 (en) * 2010-12-06 2013-11-21 Piramal Enterprises Limited` Substituted Imidazoquinoline Derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
AU2014254261B2 (en) 2013-04-15 2017-11-09 Fmc Corporation Fungicidal amides
CN105531348B (zh) * 2013-09-11 2017-11-07 默克专利有限公司 杂环化合物
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
EP3056210B1 (en) * 2013-10-11 2022-05-11 National University Corporation Tokyo Medical and Dental University Drug for prevention or treatment of spinocerebellar degeneration
CN104447740B (zh) * 2013-11-20 2017-02-22 北京富龙康泰生物技术有限公司 咪唑酮类衍生物、其药物组合物和用途
NO2714752T3 (es) 2014-05-08 2018-04-21
MX2016015923A (es) 2014-06-03 2017-02-27 Actelion Pharmaceuticals Ltd Compuestos de pirazol y su uso como bloqueadores de canales de calcio tipo t.
RS59139B1 (sr) * 2015-04-02 2019-09-30 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110023312A (zh) 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
DK3554490T3 (da) 2016-12-16 2022-02-28 Idorsia Pharmaceuticals Ltd Farmaceutisk kombination omfattende en calciumkanalblokker type T
MX2019009242A (es) 2017-02-06 2019-09-13 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-c iclopropanos.
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP2023542606A (ja) 2020-09-21 2023-10-11 ウェイ ジョン 血液脳関門透過能力を有する置換１－（３，３－ジフルオロピペリジン－４－イル）－イミダゾ［４，５－ｃ］キノリン－２－オン化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CN101824034A (zh) 2004-09-14 2010-09-08 诺华疫苗和诊断公司 咪唑并喹啉化合物
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101309687A (zh) 2005-11-04 2008-11-19 科勒制药集团公司 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法
EP2364981A1 (en) 2006-11-20 2011-09-14 Novartis AG Salts and crystalline forms of 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
ES2401822T3 (es) * 2007-07-24 2013-04-24 Novartis Ag Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR
US20090082387A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2717948C (en) 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
CA2735932C (en) 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
AU2010255727A1 (en) 2011-12-08
MA33332B1 (fr) 2012-06-01
AR076949A1 (es) 2011-07-20
NZ596487A (en) 2012-11-30
CR20110608A (es) 2012-01-16
DOP2011000373A (es) 2011-12-31
EA201101704A1 (ru) 2012-07-30
CO6470887A2 (es) 2012-06-29
TW201102386A (en) 2011-01-16
US8476294B2 (en) 2013-07-02
MX2011012943A (es) 2012-01-27
CA2763821A1 (en) 2010-12-09
IL216452A0 (en) 2012-01-31
CN102574845A (zh) 2012-07-11
KR20120034710A (ko) 2012-04-12
US20140005163A1 (en) 2014-01-02
SG176572A1 (en) 2012-01-30
JP2012528828A (ja) 2012-11-15
UY32682A (es) 2011-01-31
ECSP11011500A (es) 2012-01-31
AU2010255727B2 (en) 2013-02-28
ZA201108439B (en) 2012-08-29
GEP20156267B (en) 2015-04-14
BRPI1010621A2 (pt) 2016-06-21
EP2438064A1 (en) 2012-04-11
JP5596137B2 (ja) 2014-09-24
NI201100209A (es) 2012-02-02
TN2011000626A1 (en) 2013-05-24
CU20110221A7 (es) 2012-03-15
CL2011003052A1 (es) 2012-08-31
TWI464168B (zh) 2014-12-11
CU24064B1 (es) 2014-12-26
KR101445458B1 (ko) 2014-10-07
WO2010139731A1 (en) 2010-12-09
US20100317657A1 (en) 2010-12-16
CN102574845B (zh) 2015-09-02
UA106074C2 (uk) 2014-07-25
EA020715B1 (ru) 2015-01-30

Similar Documents

Publication Publication Date Title
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
PE20090674A1 (es) Compuestos multiciclicos
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20090511A1 (es) Imidazopiridinonas
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
ECSP088113A (es) Nuevos derivados de pirazina
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
CY1122514T1 (el) Σουλφονικος υδροξυαιθυλεστερας του αναστολεα της εξαρτωμενης απο κυκλινη πρωτεϊνικης κινασης, κρυσταλλικη μορφη αυτου και μεθοδος παρασκευης αυτου
PE20191020A1 (es) Compuestos quimicos
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ

Legal Events

Date Code Title Description
FC Refusal